comprehensive -WSS

comprehensive

author：focus 2025-09-28 02:29:59 - browse：83647

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

hotspot

focus

WSS

CRISPR base editing slashes cholesterol levels in monkeys

Congress extends some pandemic preparedness programs

The biotech scorecard for Q4: 16 stock

WHO recommends second malaria vaccine

Study suggests new cause of Down syndrome: cells linked to aging

IVG is promising — but it won’t replace IVF quite yet

focus

comprehensive

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage overpayments discussion gets experts fired up

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Health insurers' Q3 question: how much care are people getting?

Peter Hotez and the public health issue of online harassment

Merck to acquire Harpoon Therapeutics for $680 million

Guidelines to prevent youth baseball injuries need more muscle

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Drug repurposing or repositioning? The language matters

At JPM 2024, hospital systems pitch financial strength to investors

leisure time

Medicare Advantage overpayments discussion gets experts fired up

The Karikó problem: Lessons for funding basic research

Merck to acquire Harpoon Therapeutics for $680 million

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

The biotech scorecard for Q4: 16 stock

What we owe ALS patients — and why one company fell short

Wikipedia

hotspot

focus

hotspot